Engflag

Mezo

Quick links to important sections

Mezo

Mezo_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mezo

What is Mezo? A Foundational Overview of Mometasone Furoate

Property Description
Active ingredient Mometasone Furoate
Forms Cream, Ointment, Lotion, Solution
Pharmacological Class Topical Corticosteroid, Glucocorticoid
Origin Synthetic
General Purpose Provides relief from inflammation and itching

Mezo: What Type of Medicine is Mometasone Furoate?

Mezo is a medicinal preparation whose active component, Mometasone Furoate, places it firmly within the class of topical corticosteroids, which are synthetic compounds also referred to as glucocorticoids. This drug is a potent synthetic steroid compound, engineered specifically for application directly to the skin surface. Mometasone Furoate is commonly classified as a medium-potency corticosteroid, noted for its efficacy in rapidly calming inflammatory responses compared to milder alternatives. This distinction allows it to address skin inflammation that may be unresponsive to lower-strength treatments.

Composition and Forms: An Overview of the Topical Preparation

The medication is a single-ingredient product, containing only the active agent Mometasone Furoate, delivered through a specialized base intended for cutaneous use. This active substance is formulated into several distinct physical forms, including a cream, an ointment, a lotion, and a topical solution. The necessity of these multiple forms arises from the need to match the drug vehicle to the specific skin presentation, for instance, utilizing the heavier, oil-based ointment for very dry or scaly lesions to enhance absorption. Selecting the correct vehicle is key to ensuring optimal and consistent delivery of Mometasone Furoate to the target tissue.

What is the General Purpose of This Anti-Inflammatory Steroid?

The overall general purpose of Mezo is to provide pronounced relief from the physical signs of inflammation and the associated intense itching (an antipruritic effect) in affected skin areas. The compound works by initiating a chemical cascade that effectively inhibits the localized, overactive immune response. By targeting and suppressing this inflammatory process, the medication addresses the discomfort of various skin issues, restoring a sense of calm to the affected region and immediately helping to break the problematic itch-scratch cycle.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Mezo?

Mezo: Possible Side Effects and Safety Information

Official regulatory documents emphasize a safety profile primarily characterized by frequent gastrointestinal and systemic reactions alongside several serious, rare risks related to its primary pharmacological class. The information is derived from US Food and Drug Administration (FDA) prescribing labels.

Adverse Reaction Categories

Adverse reactions most commonly reported (>15% in some contexts) include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and stomach pain, which are typically dose-dependent and may subside over time. Systemic effects such as headache, dizziness, weakness, and fever/chills are also frequently noted.

Serious and Clinically Significant Risks

Regulatory authorities highlight the following serious adverse reactions, which require immediate medical attention:

  • Uterine Rupture: This is a rare, but serious and potentially fatal event, with an increased risk in patients who have a prior uterine scar or who receive multiple doses within a short period.
  • Serious Infection/Sepsis: Rare cases of serious and sometimes fatal bacterial infections, including sepsis, have been reported, sometimes without the typical initial symptom of fever. A high index of suspicion is required for patients presenting with non-specific symptoms.
  • Significant Hemorrhage: Prolonged and heavy bleeding can occur, potentially leading to the need for transfusion or other medical intervention.

Population-Specific Safety Considerations

A Boxed Warning is in effect for specific uses, mandating particular caution. The drug is contraindicated in pregnant women when used for non-obstetric conditions due to the high risk of fetal harm (including birth defects, premature birth, or abortion) and uterine complications. Effective contraception must be confirmed prior to initiating use in women of childbearing potential. Caution is also advised in patients with underlying cardiovascular or gastrointestinal conditions, as well as those with kidney impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Mezo (Mometasone Furoate) overdose primarily addresses the risk of systemic corticosteroid absorption resulting from excessive or prolonged use of the topical product. This overexposure is documented to affect the Hypothalamic-Pituitary-Adrenal (HPA) axis.

Documented Overdose Manifestations and Risks

Feature Official Regulatory Statement
Manifestations Clinical signs of Cushing's syndrome and hyperglycemia (high blood sugar).
Systemic Risk Reversible HPA axis suppression with the potential for life-threatening Glucocorticosteroid Insufficiency upon withdrawal.
Vulnerable Group Pediatric patients are officially noted to be more susceptible to systemic toxicity due to their body mass to surface area ratio.

Required Emergency Actions

Immediate medical help is required in specific circumstances, as mandated by regulatory authorities:

  • Acute Crisis: Seek urgent medical attention if signs and symptoms consistent with glucocorticosteroid insufficiency are suspected, as supplemental systemic corticosteroids may be necessary.
  • Accidental Ingestion: If the medication is swallowed, contact the Poison Control Center immediately. In cases of collapse or respiratory distress, contact emergency services.

If HPA axis suppression is documented through monitoring (e.g., ACTH stimulation testing), management involves attempting to gradually withdraw the drug, reduce the frequency of application, or substitute a less potent corticosteroid.

Therapeutic Uses of Mezo

What Mezo treats: Main Uses and Benefits

Mezo is commonly used to help with a broad range of skin disorders classified as corticosteroid-responsive dermatoses. This may include managing chronic conditions such as Psoriasis, various forms of Eczema (like Atopic Dermatitis), and Seborrheic Dermatitis. The medication is applied across therapeutic domains where additional symptomatic support is needed to ease the physiological strain associated with inflammation.

The therapeutic focus is relevant for easing symptoms related to inflammatory or irritative states, specifically intense pruritus (itching), noticeable redness (erythema), and localized swelling. It provides support that helps ease the overall symptom burden and assists with managing symptoms that interfere with daily comfort. This therapeutic approach is considered relevant for conditions where symptoms are considered unresponsive to lower-strength topical treatments, and may be part of symptomatic management during acute flare-ups.

“It contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining functional stability when symptoms are more noticeable.”

Quick Fact: Relief for Pruritus
This medication is commonly used to help with severe, persistent itching, supporting the patient by assisting with managing the symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH DailyMed Full Prescribing Information

Eligibility and Restrictions for Use

Who can and cannot use Mezo? — Official Regulatory Information

Mezo (Megestrol acetate) is an oral progestin primarily indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). The official regulatory information clearly defines specific populations who must not use the medicine.

Classification Eligibility Status Statements
Populations for Whom Use is Contraindicated Known or suspected pregnancy (requires a negative pregnancy test before treatment in females of reproductive potential). History of hypersensitivity to the drug or any component of the formulation.
Populations Requiring Special Consideration Patients with a history of thromboembolic disease (e.g., blood clots) should use this medicine with caution. Diabetic patients should be closely monitored, as the drug may exacerbate pre-existing diabetes. Therapy is only to be instituted after treatable causes of weight loss (such as other systemic infections or malignancies) are ruled out.
Age-Related Rules Pediatric use has not been established for this indication. Geriatric use generally requires cautious dose selection, reflecting the greater frequency of decreased organ function in older adults.

Pregnancy and Lactation Eligibility Status: The medicine is contraindicated in pregnancy due to the potential for fetal harm. Women who are breastfeeding should be instructed to discontinue nursing while on therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for this product is defined by two primary categories: pharmacodynamic enhancement of effects and management of specific combined adverse effects.

Interacting Medicinal Products and Categories

Category Specific Interacting Agents Interaction Type & Classification
Magnesium-containing Antacids/Supplements Magnesium hydroxide, Magnesium oxide, Magnesium carbonate, others Pharmacodynamic; Increased risk/severity of diarrhea (Moderate)
Uterotonic Agents Oxytocin, Carboprost tromethamine, others Pharmacodynamic; Augmentation of uterotonic effects (Major/Serious)

Interaction-Related Restrictions and Constraints

Co-administration with magnesium-containing antacids is generally not recommended as both agents cause diarrhea, leading to an additive effect on the gastrointestinal tract. If an antacid is required, official labeling suggests choosing one that contains aluminum or calcium instead of magnesium.

Use of this product may augment the activity of oxytocic agents (e.g., Oxytocin). This pharmacodynamic synergism increases the risk of uterine hyperstimulation. Therefore, official regulatory documentation advises against co-administration or requires a time-spacing constraint, with oxytocin typically not initiated until several hours after the last dose of this product.

The most severe interaction constraint is the absolute contraindication for reducing the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in pregnant women due to the product's documented uterotonic properties that carry a major risk of fetal harm, including uterine rupture and abortion.

Mechanism of Action

How Mezo Works

The action of Mezo is rooted in its structure as a synthetic Prostaglandin E1 ( PGE1) analogue, functioning as a direct agonist on PGE receptors, particularly the EP2 and EP3 subtypes. This interaction initiates distinct molecular cascades in various tissues. In the stomach, activation of EP3 receptors on parietal cells reduces the activity of the proton pump by lowering cyclic AMP ( cAMP) levels, thereby decreasing gastric acid production. Concurrently, Mezo increases mucus and bicarbonate secretion, modifying the mucosal barrier function.

In smooth muscle tissue, such as the myometrium, EP receptor binding triggers an increase in intracellular calcium, promoting myosin light chain kinase activation. This molecular event directly increases myometrial tone and smooth muscle contractions, resulting in a distinct change in uterine and cervical function.

Dosage and Administration Information

Mezo is strictly intended for topical use on the skin. The active component, Mometasone Furoate, is consistently formulated at a strength of 0.1% and is available in forms such as a cream, ointment, or lotion, allowing for selection based on the specific lesion type. The universal administration pattern requires applying a thin film of the product to the affected area once daily. This single-application-per-day schedule is the standard regimen for initiating a local response and maintaining its profile.

Treatment is intended for short courses and application must be discontinued immediately once satisfactory clinical control of the condition is achieved. If no improvement is observed within a period of two weeks of starting treatment, the usage pattern or diagnosis must be reassessed. The medicine is generally administered to adults and children two years of age and older, but it is not recommended for children younger than two years due to insufficient data.

Administration constraints mandate that the product must not be used with occlusive dressings (e.g., bandages or plastic wraps), as this can significantly alter the use profile, and application must be avoided on sensitive areas like the face, groin, or axillae unless specifically directed. These rules define the precise, standardized procedure for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mezo

The information below summarizes the clinical research and evidence structure that describes the evidence structure used in the regulatory evaluation of Mometasone Furoate. This overview focuses on the types of studies conducted, the parameters measured, and the recognized gaps in the research, without providing clinical advice or treatment recommendations.

Evidence for Use in Psoriasis (Plaque Psoriasis)

Research exploring Mometasone Furoate for Plaque Psoriasis primarily consists of short-term Randomized Controlled Trials (RCTs). These studies typically involved adult patients with mild to moderate disease severity. The trials were applied in research examining symptom intensity or variability, comparing the groups receiving the active substance to the groups receiving the inactive substance (placebo) or other similar topical treatments. The studies monitored outcomes linked to inflammatory or irritative states, such as objective measurements of redness, thickness, and scaling.

Evidence for Use in Eczema (Atopic Dermatitis)

Mometasone Furoate was studied for symptoms associated with Eczema/Atopic Dermatitis (AD). The evidence is drawn from numerous placebo-controlled RCTs and systematic reviews that included both adults and certain pediatric patients. Researchers explored patient-reported outcomes describing perceived discomfort, particularly pruritus (itching), and used standardized severity scales to track changes in the observed populations.

Research Gaps and What Remains Uncertain

The research base highlights areas where information is still developing. One key limitation is that long-term effects are not fully established concerning the possibility of local skin changes after extended, repeated use. Subgroup findings remain uncertain for extremely severe disease presentations, as the majority of core trials focus on mild to moderate cases. Comparative evidence is also limited for a direct, head-to-head comparison of all available formulations (cream, ointment, lotion, solution).

Key Studies & References

  1. Label: MOMETASONE FUROATE ointment - DailyMed (NIH)
  2. Label: MOMETASONE FUROATE cream - DailyMed (NIH)
  3. Frequency of application of topical corticosteroids for atopic eczema - NICE Guidance (Used for duration/frequency study context)

Frequently Asked Questions (FAQ)

Common questions about Mezo (FAQ)

Q: Is it safe to drink alcohol while I'm taking Mezo?

A: Official regulatory documents and prescribing information for topical Mezo (Mometasone Furoate) do not list any specific interaction warnings with alcohol. Patients who use this medication should consult with a healthcare professional regarding the use of alcohol.

Q: Are there any long-term side effects associated with taking Mezo?

A: Using potent topical corticosteroids like Mezo for extended, continuous periods can increase the risk of certain local effects, such as skin thinning or stretch marks, as well as systemic effects. Due to these risks, regulatory guidance specifies that use is intended for short courses.

Q: Is Mezo considered a controlled substance?

A: No, the active ingredient in Mezo, Mometasone Furoate, is a topical corticosteroid and is not scheduled as a controlled substance by U.S. regulatory agencies.

Q: How should I store Mezo at home?

A: Official information states that Mezo must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The product must not be frozen or refrigerated, and it must be kept in the original, tightly closed container.

Q: Are there any specific foods I should avoid while on Mezo?

A: Official regulatory documents for topical Mezo (Mometasone Furoate) do not list any specific restrictions or warnings regarding food that should be avoided while using the medication.

Q: Do people typically build up a tolerance to Mezo over time?

A: Regulatory documents mention that for certain conditions like psoriasis, there is a possibility that the skin may develop a form of tolerance to the topical steroid. This can sometimes lead to rebound relapses. Treatment duration is typically limited due to this potential for tolerance development.

Q: Can Mezo cause dry mouth or dry eyes?

A: Dry mouth and dry eyes are not listed among the common side effects in the official product information. However, systemic absorption can lead to ocular effects. Any visual changes, such as blurred vision, are advised to be reported to a healthcare provider.

Q: What if Mezo doesn't seem to be working for me after a few weeks?

A: Official guidelines state that if no improvement is seen within two weeks of starting treatment, the usage pattern or diagnosis is typically reassessed by a healthcare professional.

Q: Can I drive or operate machinery after taking Mezo?

A: Official regulatory documents do not list effects on the central nervous system that would typically impair the ability to drive or safely operate machinery.

Q: Are there different strengths or dosages available for Mezo?

A: The topical formulation of Mezo (Mometasone Furoate) is consistently available at one strength: 0.1% in its various physical forms (cream, ointment, lotion, and solution).

Q: Why are there warnings about Mezo and kidney function?

A: For the oral formulation of Mezo (Megestrol acetate), caution is advised for patients with kidney impairment. This is because official guidelines recognize that older adults often have a greater frequency of decreased organ function, which may require careful dose selection.

Q: Can Mezo affect mood or cause mood swings?

A: Serious systemic absorption of corticosteroids, though rare with topical use, can affect the adrenal glands and cause conditions like Cushing's syndrome. Signs of adrenal gland problems can include mood changes, weakness, or loss of appetite. These symptoms are advised to be brought to a healthcare professional's attention.

Q: Is Mezo taken once a day or multiple times a day?

A: The topical formulation of Mezo is generally prescribed for application once daily.

Q: Does taking a higher dose of Mezo make it work faster?

A: Official regulatory information does not suggest that a higher dose will make the medication work faster. Regulatory warnings indicate that using more than the recommended amount or using the product with occlusive dressings increases the risk of local and systemic side effects.

Q: Why do some people experience headaches when taking Mezo?

A: Headache is listed in the official product information as a frequently noted systemic side effect. While the precise cause for this specific reaction is not usually detailed, it is a recognized adverse reaction noted in the product information.

Q: Can Mezo be taken with antacids?

A: Official labeling advises against the co-administration of magnesium-containing antacids with Mezo because both agents can cause diarrhea, leading to an additive effect. Choosing an antacid that contains aluminum or calcium is suggested instead.

How should Mezo be stored and disposed of?

Storage and Disposal Requirements

Mezo (Mometasone Furoate) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat, moisture, and direct light.

Storage Restriction Requirement
Temperature Rule Do not freeze or refrigerate the product.
Container Rule Keep the medication in the original container and ensure it is tightly closed.
Stability Note Discard the opened tube after a specific period, such as 12 weeks for certain cream formulations.

This medication must be stored out of the sight and reach of children in a safe, secure location. Disposal instructions advise against throwing away unused or expired Mezo via household waste or wastewater. Consult a healthcare professional or follow local regulatory guidelines for proper disposal to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mezo found in:

A-Z Index: